drugset / Trial / NCT04134091

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091

Phase 2 Completed 56 enrolled Lipocine Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH.

Timeline

Start
2019-08-27
Primary completion
2021-06-24
Completion
2021-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 238 mg Oral
Subject Testosterone Undecanoate Small molecule 225 mg Oral